Skip to main content
TLSA
NASDAQ Life Sciences

Tiziana Life Sciences Reports Positive Biomarker Data for Nasal Foralumab in MS, Showing Reduced Inflammation and Neuroprotection

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.336
Mkt Cap
$159.262M
52W Low
$0.73
52W High
$2.6
52W Position info
83% above low
Off High info
49% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

TLSA sits 83% above its 52-week low of $0.73 on light trading volume (0.3× avg).

Summary

Tiziana Life Sciences announced positive new biomarker data for intranasal foralumab in MS, showing reduced inflammation and neuroprotection, which supports its ongoing Phase 2 clinical program.


Key Events · Product Development and Regulatory · TLSA

  • Positive Biomarker Data Reported

    New data from a late-breaking poster shows intranasal foralumab significantly reduced microglial activation and modulated CSF inflammatory and neuroprotective proteins in na-SPMS patients.

  • Mechanistic Rationale Strengthened

    The findings provide a direct link between reduced microglial PET signal and favorable CSF proteomic shifts, bolstering the scientific basis for the drug's mechanism of action.

  • Clinical Stabilization Observed

    Biomarker changes occurred alongside clinical stabilization or improvement in patients, with no serious treatment-related adverse events reported.

  • Supports Ongoing Phase 2 Program

    The positive data strengthens the rationale for the ongoing randomized, double-blind, placebo-controlled Phase 2a trial, with top-line data expected in the first half of 2026.


Analysis · TLSA · Life Sciences

This 6-K filing provides compelling new biomarker data for Tiziana's lead candidate, intranasal foralumab, in non-active secondary progressive multiple sclerosis (na-SPMS). The data, presented at Brigham and Women's Hospital, demonstrates that foralumab significantly reduces microglial activation and downregulates inflammatory biomarkers while upregulating neuroprotective proteins in the cerebrospinal fluid. These findings strengthen the mechanistic rationale for the ongoing Phase 2 program and offer new tools for monitoring disease modification, which is crucial for investor confidence in the drug's development.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TLSA was trading at $1.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.3M. The 52-week trading range was $0.73 to $2.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 05, 2026, 2:26 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6249
Real-time Price: $0.6204 info
Change: -$0.0045 (-0.72%) info
Market Cap: $79.603M info
TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.6204 info
Change: -$0.2696 (-30%) info
Market Cap: $79.603M info
TLSA
Nov 02, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.8685
Real-time Price: $0.6204 info
Change: -$0.2481 (-29%) info
Market Cap: $79.603M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.6204 info
Change: -$0.4296 (-41%) info
Market Cap: $79.603M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.6204 info
Change: -$0.4496 (-42%) info
Market Cap: $79.603M info